Literature DB >> 26826638

Myeloid-derived suppressor cells (MDSC) facilitate distant metastasis of malignancies by shielding circulating tumor cells (CTC) from immune surveillance.

Qiaofei Liu1, Quan Liao2, Yupei Zhao3.   

Abstract

The mechanisms of distant metastasis of malignancies largely remain unknown. Circulating tumor cells (CTC) derived from the primary cancer initiate distant metastasis by entering and traversing the bloodstream. Current methods to detect CTC are based on the notion that CTC do not express the common leukocyte antigen CD45. However, these methods neglect the fact that CTC can directly adhere to platelets and immune cells and therefore appear to be CD45-positive. The potential effects of interactions between CTC and adhesive immune cells have been largely overlooked, despite the fact that most CTC are killed by immune effector cells and only those that evade immune surveillance result in clonal expansion and metastatic lesions. It is crucial to define the characteristics that allow a select CTC population to escape immune surveillance; particularly, it must be determined whether interactions between CTC and adhesive immune cells provide a protective effect on CTC survival. If interactions between CTC and adhesive immune cells offer a selective advantage to those CTC cells, the next consideration is which characteristics of a CTC-immune cell population allow sufficient protection to facilitate immune evasion. Myeloid-derived suppressor cells (MDSC) are a large heterogeneous population of immature myeloid cells that accumulate during cancer progression to induce extensively systemic and local immunosuppression, a phenomenon that has been demonstrated to facilitate cancer distant metastasis. We hypothesize, therefore, that CTC populations interacting with adhesive immune cells will have different biological behavior than CTC populations alone. Further, we hypothesize that CTC can create a defensive shield consisting of adhesive MDSC, which allows evasion of immune surveillance and therefore facilitates distant metastatic lesions. This possibility highlights the importance of direct interactions between CTC and adhesive immune cells and suggests the potential target that the CTC-MDSC cluster represents for prevention and treatment of distant metastasis of malignancies.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26826638     DOI: 10.1016/j.mehy.2015.12.007

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  18 in total

Review 1.  Chemotherapy and tumor microenvironment of pancreatic cancer.

Authors:  Qiaofei Liu; Quan Liao; Yupei Zhao
Journal:  Cancer Cell Int       Date:  2017-07-05       Impact factor: 5.722

2.  Chemokine CCL4 Induces Vascular Endothelial Growth Factor C Expression and Lymphangiogenesis by miR-195-3p in Oral Squamous Cell Carcinoma.

Authors:  Ming-Yu Lien; Hsiao-Chi Tsai; An-Chen Chang; Ming-Hsui Tsai; Chun-Hung Hua; Shih-Wei Wang; Chih-Hsin Tang
Journal:  Front Immunol       Date:  2018-03-02       Impact factor: 7.561

Review 3.  Survival Mechanisms and Influence Factors of Circulating Tumor Cells.

Authors:  Wen-Chao Wang; Xiao-Feng Zhang; Jian Peng; Xi-Feng Li; Ai-Li Wang; Ya-Qin Bie; Le-Hua Shi; Mou-Bin Lin; Xiao-Feng Zhang
Journal:  Biomed Res Int       Date:  2018-11-01       Impact factor: 3.411

Review 4.  Liquid biopsy in pancreatic cancer: the beginning of a new era.

Authors:  Dipesh Kumar Yadav; Xueli Bai; Rajesh Kumar Yadav; Alina Singh; Guogang Li; Tao Ma; Wei Chen; Tingbo Liang
Journal:  Oncotarget       Date:  2018-06-01

5.  Association between circulating tumor cells and peripheral blood monocytes in metastatic breast cancer.

Authors:  Ugo De Giorgi; Michal Mego; Emanuela Scarpi; Antonio Giordano; Mario Giuliano; Vicente Valero; Ricardo H Alvarez; Naoto T Ueno; Massimo Cristofanilli; James M Reuben
Journal:  Ther Adv Med Oncol       Date:  2019-08-14       Impact factor: 8.168

Review 6.  Circulating Tumor Cells from Enumeration to Analysis: Current Challenges and Future Opportunities.

Authors:  Yu-Ping Yang; Teresa M Giret; Richard J Cote
Journal:  Cancers (Basel)       Date:  2021-05-31       Impact factor: 6.639

7.  CXCR2+ MDSCs promote breast cancer progression by inducing EMT and activated T cell exhaustion.

Authors:  Ha Zhu; Yan Gu; Yiquan Xue; Ming Yuan; Xuetao Cao; Qiuyan Liu
Journal:  Oncotarget       Date:  2017-12-07

Review 8.  The viable circulating tumor cells with cancer stem cells feature, where is the way out?

Authors:  Y T Luo; J Cheng; X Feng; S J He; Y W Wang; Q Huang
Journal:  J Exp Clin Cancer Res       Date:  2018-02-26

9.  Circulating ensembles of tumor-associated cells: A redoubtable new systemic hallmark of cancer.

Authors:  Dadasaheb Akolkar; Darshana Patil; Timothy Crook; Sewanti Limaye; Raymond Page; Vineet Datta; Revati Patil; Cynthe Sims; Anantbhushan Ranade; Pradeep Fulmali; Pooja Fulmali; Navin Srivastava; Pradip Devhare; Sachin Apurwa; Shoeb Patel; Sanket Patil; Archana Adhav; Sushant Pawar; Akshay Ainwale; Rohit Chougule; Madhavi Apastamb; Ajay Srinivasan; Rajan Datar
Journal:  Int J Cancer       Date:  2019-12-16       Impact factor: 7.396

Review 10.  Minimal residual disease in prostate cancer patients after primary treatment: theoretical considerations, evidence and possible use in clinical management.

Authors:  Nigel P Murray
Journal:  Biol Res       Date:  2018-09-04       Impact factor: 5.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.